Metastatic or recurrent
endometrioid adenocarcinoma of the uterine corpus is often incurable with limited treatment options. First-line treatment often includes cytotoxic
chemotherapy, which incurs significant toxicities for many patients.
Endometrial cancer, specifically endometrioid
cancer, is a
hormone-sensitive disease and, while single-agent hormonal
therapies have demonstrated clinical benefit, resistance to these agents often leads to the use of
chemotherapy. There is a lack of approved endocrine treatment options in the metastatic setting for most recurrent
endometrial cancers, representing an unmet clinical need. Emerging evidence suggests that hormonal
therapy in combination with other targeted treatments, such as
cyclin dependent kinase (CDK)4/6 inhibitors, is well tolerated and effective in select patient populations. We discuss the clinical evidence suggesting that the combination of CDK4/6 inhibitors and hormonal
therapy has the potential to represent an important addition to the first-line treatment options for patients with low-grade advanced or recurrent
endometrial cancer.